Science Explorer Interactive view Map
Company · Turku · Finland

Faron Pharmaceutical (Finland)

faronpharmaceuticals.comROR OpenAlex
Research works
19
▲ 2856% vs 2013–17
Citations
175
9.3 per fractional work
Top-10% rate
32.9%
record average 16.5%
Open access
38%
world 28%

Not ranked overall: Faron Pharmaceutical (Finland) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 1.06× its world share, 1 worksBiochemistry, Geneti…Immunology and Microbiology: 25.76× its world share, 3 worksImmunology and Micro…Neuroscience: 0.82× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 3.80× its world share, 0 worksPharmacology, Toxico…Computer Science: 0.17× its world share, 0 worksComputer ScienceMedicine: 1.57× its world share, 4 worksMedicineBusiness, Management and Accounting: 1.66× its world share, 1 worksBusiness, Management…Economics, Econometrics and Finance: 12.83× its world share, 3 worksEconomics, Econometr…Social Sciences: 0.11× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 25.8×. Every wedge is a field page.

Which research topics does Faron Pharmaceutical (Finland) publish most on?

By volume in 2022–2025: Pharmaceutical Economics and Policy, Immune cells in cancer, Innovation Policy and R&D and Cancer Immunotherapy and Biomarkers.

Pharmaceutical Economics…2Pharmaceutical Economics and Policy: 2 fractional worksImmune cells in cancer1Immune cells in cancer: 1 fractional worksInnovation Policy and R&D1Innovation Policy and R&D: 1 fractional worksCancer Immunotherapy and Biomarkers: 1 fractional worksBiosimilars and Bioanalytical Methods: 1 fractional worksPrivate Equity and Ventu…1Private Equity and Venture Capital: 1 fractional worksAcute Myeloid Leukemia Research: 0 fractional worksPhagocytosis and Immune Regulation: 0 fractional worksImmunotherapy and Immune Responses: 0 fractional worksFerroptosis and cancer prognosis: 0 fractional works
Economics and EconometricsImmunologyOncologyAccounting2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Pharmaceutical Economics and Policy Economics and Econometrics 2 works
  2. 2 Immune cells in cancer Immunology 1 works
  3. 3 Innovation Policy and R&D Economics and Econometrics 1 works
  4. 4 Cancer Immunotherapy and Biomarkers Oncology 1 works
  5. 5 Biosimilars and Bioanalytical Methods Immunology 1 works
  6. 6 Private Equity and Venture Capital Accounting 1 works
  7. 7 Acute Myeloid Leukemia Research Hematology 0 works
  8. 8 Phagocytosis and Immune Regulation Immunology 0 works
  9. 9 Immunotherapy and Immune Responses Immunology 0 works
  10. 10 Ferroptosis and cancer prognosis Pulmonary and Respiratory Medicine 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available38.3%not open61.7%

World: 28% of research is openly available.

with international co-authors31.6%domestic only68.4%

World: 19% is written across borders.

How has Faron Pharmaceutical (Finland)'s research output changed?

Output in 2018–2022 was 2856% higher than in 2013–2017.

1990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Turku

All research institutions in Turku

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.